Targeted drug delivery system for transplanted organs
Official title: A Bio-orthogonal Targeting System for Precision Drug Delivery to Vascular Endothelium in Transplanted Organs
Funded at Boston University (Charles River Campus) · NIH-10998558 · Data updated 2026-11-12
This study is exploring a new way to help organ transplants work better by delivering medication directly to the transplanted organs, which could mean fewer side effects and less need for long-term medication after surgery.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University (Charles River Campus) NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2029 |
| Funding year | 2024 |
| Award (this year) | $53,974 |
| NIH project number | 1F30HL176145-01 |
| Project ID | NIH-10998558 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals undergoing organ transplantation who require immunosuppressive therapy.
✕Less likely to help
Patients who are not candidates for organ transplantation or those who do not require immunosuppressive therapy may not benefit from this research.
What this research studies
This research investigates a novel approach to improve the success of organ transplants by developing a targeted drug delivery system. It aims to reduce the need for lifelong immunosuppressive therapy, which can lead to serious health complications. By using a bio-orthogonal targeting system, the researchers plan to deliver immunosuppressive drugs directly to the vascular endothelium of transplanted organs, minimizing side effects and enhancing organ viability. The approach involves treating donor organs with a special targeting moiety during ex vivo perfusion before transplantation.
Why it matters
Potential benefit: If successful, this research could significantly improve the health outcomes of transplant patients by reducing the risks associated with immunosuppressive therapy.
How similar studies have gone: While the approach is innovative, similar strategies in targeted drug delivery have shown promise in other medical fields, suggesting potential for success in this area as well.
Where this research is happening
-
Boston University (Charles River Campus)
Boston, United States Active
Researchers
- Principal investigator: Pearlman Morales, Aria — Boston University (Charles River Campus)
- Study coordinator: Pearlman Morales, Aria
Related research
Other NIH-funded projects on the same topics.
-
How Arousal Changes How We See the World
This grant studies how moments of alertness or mood changes alter how the brain processes what we see.
-
NGF Metabolism as a biomarker for cognitive decline in familial Alzheimer's disease
Researchers are studying whether patterns in nerve growth factor pathways in blood and CSF can signal early, preclinical stages of Alzheimer's in people with genetic risk.
-
NGF metabolism as an early biomarker for cognitive decline in familial Alzheimer's disease
This project tests whether NGF pathway proteins in blood and CSF can signal early, preclinical changes in people with familial Alzheimer’s disease.
-
Ultra-High Density wearable brain monitoring in real life
Aims to make advanced wearable brain sensors that work in daily life to track brain activity alongside movement, perception, and communication.
-
A new method to image brain activity noninvasively using speckle contrast spectroscopy
A new, noninvasive imaging technique called speckle contrast optical spectroscopy (SCOS) could help measure brain blood flow in people, including those with brain injuries or neurodegenerative conditions.
-
NGF Metabolic Dysfunction as a Marker of Cognitive Decline in Autosomal Dominant Alzheimer's Disease
This project looks at nerve growth factor pathways in people with a genetic form of Alzheimer's to see if blood and spinal fluid markers can identify early brain changes before symptoms appear.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.